| SC 13D/A | 2020-01-16 | DUGGAN ROBERT W | Summit Therapeutics plc | 231,048,661 | 64.9% | EDGAR |
| SC 13D/A | 2019-12-27 | DUGGAN ROBERT W | Summit Therapeutics plc | 269,368,810 | 74.7% | EDGAR |
| SC 13D/A | 2019-12-10 | DUGGAN ROBERT W | Summit Therapeutics plc | 78,288,205 | 48.8% | EDGAR |
| SC 13G/A | 2019-02-14 | Point72 Asset Management, L.P. | Summit Therapeutics plc | 2,229,955 | 2.7% | EDGAR |
| SC 13D | 2019-01-22 | DUGGAN ROBERT W | Summit Therapeutics plc | 78,288,205 | 48.8% | EDGAR |
| SC 13D/A | 2019-01-11 | LANSDOWNE PARTNERS (UK) LLP | Summit Therapeutics plc | 21,143,500 | 13.2% | EDGAR |
| SC 13G/A | 2018-02-14 | Point72 Asset Management, L.P. | Summit Therapeutics plc | 3,928,000 | 5.3% | EDGAR |
| SC 13D/A | 2018-01-30 | LANSDOWNE PARTNERS (UK) LLP | Summit Therapeutics plc | 19,060,500 | 25.9% | EDGAR |
| SC 13D/A | 2017-09-20 | LANSDOWNE PARTNERS (UK) LLP | Summit Therapeutics plc | 19,060,500 | 27.1% | EDGAR |
| SC 13G/A | 2017-02-14 | Point72 Asset Management, L.P. | Summit Therapeutics plc | 4,630,995 | 7.6% | EDGAR |
| SC 13G/A | 2016-02-16 | Point72 Asset Management, L.P. | Summit Therapeutics plc | 4,650,000 | 7.6% | EDGAR |
| SC 13D/A | 2015-03-26 | LANSDOWNE PARTNERS (UK) LLP | Summit Therapeutics plc | 15,727,170 | 25.8% | EDGAR |
| SC 13D | 2015-03-16 | LANSDOWNE PARTNERS (UK) LLP | Summit Therapeutics plc | 15,727,170 | 27.0% | EDGAR |
| SC 13G | 2015-03-11 | Point72 Asset Management, L.P. | Summit Therapeutics plc | 3,856,105 | 6.6% | EDGAR |